PATIENT BARRIERS TO BREAST CANCER CLINICAL TRIALS

该项目的长期目标是增加可访问性和 非洲裔美国人和高加索人参与临床试验 患有乳腺癌的女性。临床试验往往是最先进的 医学实践(Roberson，1994)，但临床试验的收益通常是 Low(Friedman&Dorr，1990；Johansen等人，1991；Bennett，1993)。 尽管临床试验收益率低的原因有很多 一般来说，很少有实证证据证明这些因素。 影响妇女临床试验的可及性和参与度 患有乳腺癌。关于障碍的知识甚至更少 少数民族女性乳腺癌的诱因。因此，它 建议项目的意图是基于经验获得 了解影响可及性的患者因素和 乳腺癌妇女参与临床试验。vbl.使用 调查研究方法，该项目将收集200名女性的数据 哪些是肿瘤内科诊所的新乳癌患者？ 底特律的哈珀医院。应用Anderson‘s的修改版本 (1975,1995)健康行为模式，该项目将从 非裔美国人和高加索女性乳腺癌的诱因， 可能影响临床试验的使能、需要和求助因素 参与。在分析数据之后，调查结果将由 消费者团体，努力制定更有效的战略来 提高乳腺癌临床试验可及性和参与度。它 预计该项目将需要2年时间才能完成。具体的 目标是：1)确定患者的易患因素(人口统计， 社会结构、健康信念)和能力(经济、家庭和 社区资源)乳腺癌妇女参与临床 试验；2)确定影响他们的疾病“需要”因素 参与临床试验；3)确定求助模式 影响他们参与临床试验的因素；4)评估 不同种族(非裔美国人和高加索女性)的因素差异 影响临床试验的可及性和参与性；以及5)设计 扩大非洲人的可及性和参与度的战略 美国和高加索乳腺癌妇女正在进行临床试验。

The long-range goal of this project is to increase accessibility and participation in clinical trials among African American and Caucasian women with breast cancer. Clinical trials often present state of the art medical practice (Roberson, 1994), yet accrual to clinical trials is often low (Friedman & Dorr, 1990; Johansen et al, 1991; Bennett, 1993). Although there are many reasons given for low clinical trial accrual generally, there is very little empirical evidence which documents factors affecting accessibility and participation in clinical trials for women with breast cancer. There is even less knowledge about barriers and motivating factors for minority women with breast cancer. Accordingly, it is the intent of the proposed project to acquire empirically based knowledge of patient factors which affect the accessibility and participation of women with breast cancer in clinical trials. Using survey research methodology, the project will collect data from 200 women who are new breast cancer patients in the medical oncology clinic at Harper Hospital in Detroit. Applying a modified version of Anderson's (1975, 1995) health behavior model, the project will collect data from African American and Caucasian women with breast cancer on predisposing, enabling, need, and helpseeking factors which may influence clinical trial participation. After data are analyzed, findings will be reviewed by consumer groups in an effort to devise more effective strategies to increase breast cancer clinical trial accessibility and participation. It is projected that the project will take 2 years to complete. The specific aims are: 1) to determine patient factors which predispose (demographic, social structural, health beliefs) and enable (economic, family and community resources) women with breast cancer to participate in clinical trials; 2) to determine illness "need" factors which affect their participation in clinical trials; 3) to determine helpseeking patterns which affect their participation in clinical trials; 4) to assess differences by race (African American and Caucasian women) in factors affecting clinical trial accessibility and participation; and 5) to devise strategies to expand the accessibility and participation of African American and Caucasian women with breast cancer in clinical trials.